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Mitomycin, ifosfamide and cis-platin in non-small cell lung cancer:
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'Queen Elizabeth Hospital, Birmingham, B15 2TH; and 2Manor Hospital, Walsall WS2 9PS, UK.
Summary Mitomycin, ifosfamide and cis-platin are three of the most active single agents in the chemo-
therapy of non-small cell lung cancer. We have combined them for a phase 2 study in patients with
inoperable non-small cell lung cancer. The regimen ('MIC') comprised: mitomycin 6mg m-2, ifosfamide
3gm-2 and cis-platin 50mgm-2, with routine use of lorazepam, dexamethasone and high dose metoclopra-
mide for anti-emesis. Seventy-four ambulatory patients with untreated, limited (LD) or extensive (ED) disease
have entered this study, and 66 are evaluable for response. Thirty patients (45%) have achieved partial
remission and 7 (11%) complete remission, as assessed radiologically. The overall response rate is thus 56%
(95% confidence interval 44%-68%). There have been 29/43 responses in LD (67%, 95% CI 53%-81%) and
8/23 in ED (35%, 95% CI 15%-55%). The median response duration, measured from the start of treatment
is 8.75 months. The median survival for the whole group is 9.2 months. The principal toxicity was nausea and
vomiting which was severe or prolonged (>48h) for one or more courses, in 9% of patients. Performance
status (PS) and weight were assessed before, and 3 weeks after the last course of chemotherapy. Fifteen (of 31
evaluable) responders improved their PS and only 1 responder deteriorated. Twenty-one of the 28 evaluable
non-responders had no change in PS. The difference in PS change between responders and non-responders is
highly significant (P=0.002). Thirty evaluable responders experienced a mean increase in weight of 2.9% with
treatment, whereas 24 evaluable non-responders had a mean weight loss of 3.8%. This change is also highly
significant (P=0.0013). MIC is clearly a well tolerated regime and among the most active combinations in
non-small cell lung cancer. It will now be tested in a randomized trial against no chemotherapy.
Non-small cell lung cancer (NSCLC) is the commonest
malignant disease in the western world and is among the
most chemoresistant. There are only 5 drugs (ifosfamide,
mitomycin, cis-platin, vinblastine and vindesine) which, when
tested as single agents in large numbers, produce major
responses in 15% or more of cases (Kris et al., 1985).
Mitomycin, ifosfamide and cis-platin have been associated
with response rates of 20%, 26% and 20% respectively and
are the 3 most active agents (Bakowski et al., 1983). We
have combined ifosfamide with mitomycin in a recent phase
2 study in NSCLC (Chetiyawardana et al., 1985). Thirty
patients were assessable for response to chemotherapy - 8
achieving partial remission (PR) and 5 complete remission
(CR). The overall response rate to chemotherapy was thus
43%. Cis-platin and ifosfamide have demonstrated synergism
in experimental models (Goldin, 1982). Although both
agents are associated with severe nausea and vomiting, a
trial of anti-emetic therapy in our unit suggested that the
combination of high dose metoclopramide infusion, loraze-
pam and dexamethasone would allow these drugs to be
combined with acceptable subjective toxicity (O'Brien et al.,
1987).
Thus in January 1986 we commenced a phase 2 study of
mitomycin, ifosfamide and cis-platin (MIC) in inoperable
NSCLC. In addition to assessing objective response, toxicity
and survival we have systematically monitored performance
status (PS) and weight.
Patients and methods
Previously untreated, consenting, ambulatory (WHO perfor-
mance status 0, 1 or 2*) patients aged 70 or less, with
inoperable, histologically confirmed NSCLC which was mea-
surable or evaluable, were eligible for this phase 2 study.
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*WHO Performance scale: WHO 0, Able to carry out all normal
activity without restriction; WHO 1, Restricted in physically stre-
nuous activity but ambulatory and able to carry out light work;
WHO 2, Ambulatory and capable of all self-care but unable to carry
out any work, up and about >50% of waking hours; WHO 3,
Capable of only limited self-care, confined to bed or chair more
than 50% of waking hours; WHO 4, Completely disabled, cannot
carry on any self-care, totally confined to bed or chair.
Patients were staged clinically and, where indicated, had
liver, bone and brain scans. Those with intracerebral metas-
tases were excluded.
Limited disease is defined as tumour confined to one
hemithorax with or without ipsilateral node involvement.
Extensive disease refers to any patient with evidence of
tumour beyond these limits.
The treatment schedule, which consisted of mitomycin
6mgm 2 i.v. bolus, ifosfamide 3gm-2 i.v. infusion over 3h,
and cis-platin 50mgm-2 i.v. infusion over I h, is given in
full in Figure 1. Courses were repeated every 21 days to a
Oh Metoclopramide 1 mgkg- i.v. in 100 ml 0.9% saline
over 30min
0.5h Dexamethasone 8mg in 50ml 0.9% saline i.v. over
15min
Lorazepam 2mgm-2 in 50ml 0.9% saline over 15min
l.Oh Metoclopramide 9mgkg I i.v. made up as 24h
infusion administered by infusion pump
Mitomycin C 6mgm-2 - bolus
Ifosfamide 3gm-2+mesna 1.0gm-2 in I1 0.9% saline
over 3 h
4.0h Frusemide 40mg p.o.
Dexamethasone 4mg in 50ml
0.9% saline short infusion over 3h
then s
1 1 0.9% saline+20mmol KCI
7.0h Mesna 500 mgm-2 in 50ml
0.9% saline short infusion
then
cis-platin 50mgm-2 i.v. in
250ml 0.9% saline
8.0h -Dexamethasone 4mg in 50ml
0.9% saline short infusion
then
mesna 500 mgm -2 in 50ml
0.9% saline short infusion
then
1 1 0.9% saline+20mmol KCI
12.0h
16.0h
20.0h
24.0h
I
I
over 1 h
over 6h
- Dexamethasone 4mg in 50ml 0.9% saline over
J 10 min
Figure 1 Schedule for chemotherapy, antiemetics and fluids for
the MIC regimen.
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maximum of 4 in responding patients who had not exper-
ienced unacceptable toxicity.
Patients were fully reassessed after a maximum of 4
courses of chemotherapy. Response was assessed clinically
and with chest X-ray in all cases using WHO criteria (WHO,
1979). Staging investigations were repeated as appropriate.
Weight and WHO performance status were assessed before,
and 3 weeks after completing chemotherapy. Survival curves
were plotted using the Kaplan-Meier method and were
compared by the logrank test. Changes in weight and
performance status between responders and non-responders
were compared using Student's t test and the Mann-Whitney
U test, respectively.
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Results
Since January 1986, 74 patients have entered this study and
66 are evaluable for response. Pre-treatment characteristics
of the study patients are given in Table I. Thirty patients
achieved partial remission (45%) and 7 have achieved com-
plete remission (11%) as assessed radiologically. The overall
response rate is thus 56% (95% confidence interval 44-
68%). There have been 29/43 responses in limited disease
(67%, 95% CI 53-81%) and 8/23 in extensive disease (35%,
95% CI 15-55%). Response rates are related to histology
and extent of disease in Table II. The duration of response is
shown in Figure 2. The median response duration, measured
from the start of treatment was 8.75 months and the median
overall survival was 9.2 months (Figure 3). The median
survival of responders was 12 months and for non-
responders 5 months (Figure 4, x2= 13.02; P =0.0003
logrank).
Toxicity was generally mild and consisted principally of
nausea and vomiting. Six of 67 evaluable patients exper-
ienced severe or prolonged (>48 h) nausea and vomiting
after one or more courses of MIC and one declined further
therapy. Ten patients had no nausea or vomiting. For the
remainder it was mild and short-lived. Haematological toxi-
city was monitored prior to each of 213 courses and during
the nadir phase (day 8-16) in 130 courses. In 48% of courses
there was leucopenia (WCC <3.0 x 1091 -1) and/or thrombo-
cytopenia (platelets <100 x 109 1 -1) during the nadir period
but in only 8% did this persist to day 21 and delay further
courses. There have been 2 leucopenia-related infections
requiring admission and one treatment-related infective
Table I Pre-treatment patient characteristics
Total 74
Male/female 65/9
Age range (median) 27-70 (61)
WHO performance status 0 6
1 28
2 35
not known 5
Histological type: Epidermoid carcinoma 62
Adenocarcinoma 9
Adeno-squamous carcino-
ma 3
Limited/extensive disease 50/24
Table II Response characteristcs
Total 74
Total evaluable for response 66
On treatment 6
Response unassessable 2
Partial response (%) 30 (45%)
Complete response (%) 7 (11%)
Overall response rate 56%
Responders/no. eval. (%) epidermoid carcinoma 32/55 (58%)
adenocarcinoma 3/8
adeno-squamous carcinoma 2/3
limited disease 29/43 (67%)
extensive disease 8/23 (35%)
Time (months)
Figure 2 Actuarial curve of remission duration in 37 complete
and partial responders to MIC, with 95% confidence intervals
(dotted lines) and numbers at risk given in brackets [n].
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Figure 3 Actuarial survival curve for all 74 patients entered
with 95% confidence intervals (dotted lines) and numbers at risk
given in brackets [n].
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Figure 4 Actuarial survival curves of 37 responders and 29 non-
responders to MIC (P=0.0003, logrank test).
death during the leucopenic phase. Anaemia (Hb.
<lOgdl- ) was present following 28% of courses, and
serum creatinine > 125pmol]l- after 5%. All patients
receiving 2 or more courses experienced alopecia.
Thirty-one responding patients and 28 non-responders
were evaluable for PS assessments. Before treatment there
was no difference between responders and non-responders in
PS (P=0.73; Table III) Fifteen responders improved their PS
(12 by I WHO grade and 3 by 2 grades) and only one
responder deteriorated. Twenty-one of the 27 evaluable non-
responders had no change in PS, three increased and 4
decreased (3 by I WHO grade and I by 2 grades). The
difference in PS change between responders and non-
responders was highly significant (P=0.002). There was no
difference in weight between responders and non-responders
before treatment (mean 69.0kg and 70.75kg respectively,
t50 =0.56; P=0.58). Thirty evaluable responders experienced
a mean increase in weight of 2.9% with treatment (Figure 5),
whereas 24 evaluable non-responders had a mean weight loss
of 3.8%. The difference in this change was also highly
significant (t,2 =3.41; P=0.0013).
0MITOMYCIN, IFOSFAMIDE AND CIS-PLATIN IN NSCLC 361
Table III WHO performance scores before
and after chemotherapy (CT) in responders and
non-responders
Pre-CT Post-CT
Responders:
WHO 0 2 7
WHO 1 12 17
WHO 2 17 7
Non-responders:
WHO 0 4 4
WHO 1 9 11
WHO 2 15 10
WHO 3 - 2
WHO 4 - 1
+30-
+20
Non-responders
+10 Mean ; 1Ma
+2%
0- Mdan 0= + edian=
-10 -1-3.8%
pre-MIC post-M C
Responders -20_-_. -20-
pre-MIC post-MIC
Figure 5 Percent change in weight from the start of treatment
to 3 weeks after final course of MIC, in 30 responders and 24
non-responders. The difference in weight change is highly signifi-
cant (t52 =3.41; P=0.0013).
Discussion
An objective response rate of 56%, with 11% complete
responses suggest that the MIC combination is among the
most active yet reported in this disease. A smaller series
recently reported from Madrid has shown similar results
(Giron et al., 1987). Cis-platin and mitomycin have been
combined with vindesine and response rates of the same
order as reported here have been seen (Kris et al., 1986).
Thus there is increasing evidence that combinations including
cis-platin, mitomycin, ifosfamide, vindesine (or vinblastine)
can induce major responses in over 50% of patients with
NSCLC. The important questions behind these response
data are: (1) Do patients experience improvements in perfor-
mance status to mirror the objective response? (2) How far
do the side-effects of treatment outweigh any disease pallia-
tion? (3) What, if any, is the survival advantage conferred by
treatment?
A recent study from Bakker et al. (1986) reported a
response rate of 48% in 28 NSCLC patients with cis-platin,
vindesine and bleomycin. Performance status and weight
dropped significantly during chemotherapy in both res-
ponders and non-responders. Although PS approached pre-
treatment scores after discontinuation of chemotherapy in
the responders, the authors conclude that treatment-
associated toxicity (principally vomiting) and deterioration of
the patient's well-being offset any potential survival advan-
tage for the majority of patients. The response rate in the
present study is similar but we observe important differences
in these parameters. Almost half the responders improved
PS, and the large majority of non-responders experienced no
change. Furthermore patients who responded to MIC had a
mean weight gain with 12 weeks treatment, compared to a
mean loss of weight in those not responding. The difference
between the 2 studies may be that MIC is more active and
the responses are associated with greater clinical improve-
ment. It may also relate to the anti-emetic regimen and cis-
platin dose: domperidone 10mg every 4h as used in
Bakker's study is inadequate anti-emetic therapy for full
dose cis-platin chemotherapy.
The question of survival advantage conferred by chemoth-
erapy can only be answered in a randomised trial. According
to one review mitomycin, ifosfamide and cis-platin are the 3
most active single agents in NSCLC (Bakowski & Creach,
1983), and when combined in the schedule used here, are
well tolerated in the majority of patients. Objective response
is associated with prompt clinical improvement in a big
enough proportion of these cases to make a large scale
randomised trial against no chemotherapy a worthwhile
venture. We are now conducting a randomised comparison
of MIC followed by radiotherapy versus radiotherapy alone
in limited stage, inoperable NSCLC.
We would like to thank the nurses, who cared for these patients, the
clinicians who referred them, in particular Dr J. Sheldon, and Sister
Law, for her help in collecting the data. We would also like to
acknowledge the statistical help of Dr K. Kelly and the facilities of
the West Midlands Cancer Research Campaign Clinical Trials Unit
at the Queen Elizabeth Hospital, Birmingham.
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